JP2012017342A5 - - Google Patents

Download PDF

Info

Publication number
JP2012017342A5
JP2012017342A5 JP2011228229A JP2011228229A JP2012017342A5 JP 2012017342 A5 JP2012017342 A5 JP 2012017342A5 JP 2011228229 A JP2011228229 A JP 2011228229A JP 2011228229 A JP2011228229 A JP 2011228229A JP 2012017342 A5 JP2012017342 A5 JP 2012017342A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
capsular saccharide
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011228229A
Other languages
English (en)
Japanese (ja)
Other versions
JP5314745B2 (ja
JP2012017342A (ja
Filing date
Publication date
Priority claimed from GBGB0220198.6A external-priority patent/GB0220198D0/en
Application filed filed Critical
Publication of JP2012017342A publication Critical patent/JP2012017342A/ja
Publication of JP2012017342A5 publication Critical patent/JP2012017342A5/ja
Application granted granted Critical
Publication of JP5314745B2 publication Critical patent/JP5314745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011228229A 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造 Expired - Fee Related JP5314745B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220198.6 2002-08-30
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004532625A Division JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造

Publications (3)

Publication Number Publication Date
JP2012017342A JP2012017342A (ja) 2012-01-26
JP2012017342A5 true JP2012017342A5 (2) 2013-05-30
JP5314745B2 JP5314745B2 (ja) 2013-10-16

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532625A Expired - Fee Related JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造
JP2011228229A Expired - Fee Related JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004532625A Expired - Fee Related JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造

Country Status (16)

Country Link
US (2) US8895516B2 (2)
EP (1) EP1534342B1 (2)
JP (2) JP5268222B2 (2)
CN (2) CN101863998B (2)
AT (1) ATE319481T1 (2)
AU (1) AU2003260921B2 (2)
BR (1) BR0314089A (2)
CA (1) CA2497167C (2)
DE (1) DE60303961T2 (2)
DK (1) DK1534342T3 (2)
ES (1) ES2260682T3 (2)
GB (1) GB0220198D0 (2)
MX (1) MXPA05002315A (2)
NZ (1) NZ538703A (2)
RU (2) RU2005108992A (2)
WO (1) WO2004019992A1 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
MX2007013881A (es) 2005-05-06 2008-10-22 Novartis Vaccines & Diagnostic Inmunogenos para vacunas de meningitides-a.
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
WO2010027499A2 (en) 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE034251T2 (en) * 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016170186A1 (en) * 2015-04-23 2016-10-27 Synaffix B.V. PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
JP2019508468A (ja) * 2016-03-15 2019-03-28 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2020182635A1 (en) * 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
US6472506B1 (en) * 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
JP4182269B2 (ja) * 1997-08-08 2008-11-19 ベーリングウエルケ、アクティエンゲゼルシャフト 生体分子のポリサッカライド接合体
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Similar Documents

Publication Publication Date Title
JP2012017342A5 (2)
AU2008227128B2 (en) Conjugates of synthetic TLR agonists and uses therefor
JP2013136639A5 (2)
JP2010132925A5 (2)
JP2010515718A5 (2)
TWI633112B (zh) 醣類-醣脂類結合性疫苗
JP2022068303A (ja) 多価肺炎球菌多糖体-タンパク質複合体組成物
JP2014218516A5 (2)
EA023725B1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
JP2008526939A5 (2)
JP2011528710A5 (2)
JP2021001182A5 (2)
RU2007145219A (ru) Иммуногены для вакцин против менингита а
JP2017532321A (ja) 肺炎連鎖球菌血清型8に対するワクチン
CN110302375A (zh) 一种糖缀合物及其用途
Mat Rani et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers
JP6630440B2 (ja) ストレプトコッカス ニューモニアエ(Streptococcus pneumoniae)血清型2に対する合成ワクチン
WO2012145626A1 (en) Synthetic oligosaccharides for staphylococcus vaccine
JP2023502276A5 (2)
JP2009517350A (ja) ビスアシルオキシプロピルシステイン複合体に基づく新規なアジュバント及び誘導体並びに医薬組成物におけるその使用
JP5428017B2 (ja) ワクチン剤
WO2013178236A1 (en) Carbohydrate-glycolipid conjugate vaccines
JP2011527340A5 (2)
JP2007518732A5 (2)